Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QPI-1007 in Acute NAION
NCT02341560Phase 3Terminated
- Sponsor
- Quark Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Jul 2019
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of QPI-1007 in non-arteritic anterior ischemic optic neuropathy (NAION) (3 arms), sponsored by Quark Pharmaceuticals. Primary endpoints: Proportion of subjects losing >= 15 letters in BCVA at 12 months and Safety and tolerability at 12 months. Started Feb 2016; status: terminated.
02
Drugs
QPI-1007
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on NCT02341560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341560.